| Functional genomic landscape of acute myeloid leukaemia JW Tyner, CE Tognon, D Bottomly, B Wilmot, SE Kurtz, SL Savage, ... Nature 562 (7728), 526-531, 2018 | 1111 | 2018 |
| Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia GJ Roboz, CD DiNardo, EM Stein, S de Botton, AS Mims, GT Prince, ... Blood, The Journal of the American Society of Hematology 135 (7), 463-471, 2020 | 345 | 2020 |
| In vivo imaging of microglial activation with [11C](R)‐PK11195 PET in corticobasal degeneration A Gerhard, J Watts, I Trender‐Gerhard, F Turkheimer, RB Banati, K Bhatia, ... Movement disorders: official journal of the Movement Disorder Society 19 (10 …, 2004 | 162 | 2004 |
| Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML S Choe, H Wang, CD DiNardo, EM Stein, S de Botton, GJ Roboz, ... Blood advances 4 (9), 1894-1905, 2020 | 154 | 2020 |
| Integrative analysis of drug response and clinical outcome in acute myeloid leukemia D Bottomly, N Long, AR Schultz, SE Kurtz, CE Tognon, K Johnson, M Abel, ... Cancer cell 40 (8), 850-864. e9, 2022 | 142 | 2022 |
| Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms DP Steensma, M Wermke, VM Klimek, PL Greenberg, P Font, ... Leukemia 35 (12), 3542-3550, 2021 | 121 | 2021 |
| Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid-and lymphoid-derived hematologic malignancies SE Kurtz, CA Eide, A Kaempf, V Khanna, SL Savage, A Rofelty, I English, ... Proceedings of the National Academy of Sciences 114 (36), E7554-E7563, 2017 | 104 | 2017 |
| Acute promyelocytic leukemia: what is the new standard of care? JM Watts, MS Tallman Blood reviews 28 (5), 205-212, 2014 | 104 | 2014 |
| Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML MA Sekeres, J Watts, A Radinoff, MA Sangerman, M Cerrano, PF Lopez, ... Leukemia 35 (7), 2119-2124, 2021 | 98 | 2021 |
| Results of a clinical trial of H3B-8800, a splicing modulator, in patients with myelodysplastic syndromes (MDS), acute myeloid leukemia (AML) or chronic myelomonocytic leukemia … DP Steensma, M Wermke, VM Klimek, PL Greenberg, P Font, ... Blood 134, 673, 2019 | 97 | 2019 |
| Aurora kinase a inhibition provides clinical benefit, normalizes megakaryocytes, and reduces bone marrow fibrosis in patients with myelofibrosis: a phase I trial N Gangat, C Marinaccio, R Swords, JM Watts, S Gurbuxani, A Rademaker, ... Clinical cancer research 25 (16), 4898-4906, 2019 | 76 | 2019 |
| Recent advances in the understanding and treatment of acute myeloid leukemia J Watts, S Nimer F1000Research 7, 2018 | 76 | 2018 |
| Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study A Hochhaus, C Gambacorti-Passerini, C Abboud, BT Gjertsen, ... Leukemia 34 (8), 2125-2137, 2020 | 74 | 2020 |
| Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial JM Watts, MR Baer, J Yang, T Prebet, S Lee, GJ Schiller, SN Dinner, ... The Lancet Haematology 10 (1), e46-e58, 2023 | 71 | 2023 |
| Development of 2 bromodomain and extraterminal inhibitors with distinct pharmacokinetic and pharmacodynamic profiles for the treatment of advanced malignancies G Falchook, S Rosen, P LoRusso, J Watts, S Gupta, CC Coombs, ... Clinical Cancer Research 26 (6), 1247-1257, 2020 | 70 | 2020 |
| CARM1 is essential for myeloid leukemogenesis but dispensable for normal hematopoiesis SM Greenblatt, N Man, PJ Hamard, T Asai, D Karl, C Martinez, D Bilbao, ... Cancer cell 33 (6), 1111-1127. e5, 2018 | 66 | 2018 |
| KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study RT Swords, PL Greenberg, AH Wei, S Durrant, AS Advani, MS Hertzberg, ... Leukemia research 50, 123-131, 2016 | 66 | 2016 |
| Advances in acute myeloid leukemia: recently approved therapies and drugs in development M Stanchina, D Soong, B Zheng-Lin, JM Watts, J Taylor Cancers 12 (11), 3225, 2020 | 65 | 2020 |
| Oncogenic TRK fusions are amenable to inhibition in hematologic malignancies J Taylor, D Pavlick, A Yoshimi, C Marcelus, SS Chung, JF Hechtman, ... The Journal of clinical investigation 128 (9), 3819-3825, 2018 | 64 | 2018 |
| Ex-vivo sensitivity profiling to guide clinical decision making in acute myeloid leukemia: A pilot study RT Swords, D Azzam, H Al-Ali, I Lohse, CH Volmar, JM Watts, A Perez, ... Leukemia Research 64, 34-41, 2018 | 55 | 2018 |
